Christopher Moreau, CEO and Director of Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) highlights how DMT represents a potential new way of thinking about treatment for stroke.
Algernon Pharmaceuticals is a Canadian clinical-stage drug development company investigating multiple drugs with global unmet medical needs.